Oncologic Emergencies

Critical Care Clinics

Volumn 26, Issue 1, 2010, Pages 181-205

  Behl, Deepti ^a   Hendrickson, Andrea Wahner ^a   Moynihan, Timothy J ^a  

^a Mayo Clinic   (United States)

Author keywords

Hypercalcemia; Hyperviscosity; Malignant airway obstruction; Malignant spinal cord compression

Indexed keywords

ALKYLATING AGENT; ALLOPURINOL; ALUMINUM HYDROXIDE; BICARBONATE; BLEOMYCIN; CALCITONIN; CARBOPLATIN; CORTICOSTEROID; DEXAMETHASONE; FUROSEMIDE; GALLIUM NITRATE; GLUCONATE CALCIUM; HYDROCORTISONE; INSULIN; LOOP DIURETIC AGENT; MANNITOL; MITHRAMYCIN; MITOMYCIN C; NUCLEOSIDE ANALOG; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; POLYSTYRENESULFONATE SODIUM; PORPHYRIN; PREDNISONE; RASBURICASE; SALBUTAMOL; STEROID; UNINDEXED DRUG; VITAMIN D; ZOLEDRONIC ACID;

AIRWAY OBSTRUCTION; BRAIN METASTASIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DECOMPRESSION SURGERY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; EMERGENCY MEDICINE; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPERVISCOSITY SYNDROME; HYPOCALCEMIA; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INTESTINE PERFORATION; INTRACRANIAL HYPERTENSION; LEUKOCYTOSIS; MALIGNANT SPINAL CORD COMPRESSION; ONCOLOGY; PARATHYROID HORMONE RELEASE; PERICARDIAL EFFUSION; PRIORITY JOURNAL; RECTUM HEMORRHAGE; REVIEW; RISK FACTOR; SPINAL CORD COMPRESSION; STENT; SUPERIOR CAVA VEIN SYNDROME; SYMPTOMATOLOGY; TUMOR LYSIS SYNDROME; ULCER;

EMERGENCIES; EMERGENCY TREATMENT; HUMANS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 70449738861     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2009.09.004     Document Type: Review

References (98)

1. Abeloff M.D. Hypercalcemia. Abeloff's clinical oncology. 4th edition (2004), Churchill Livingston, Philadelphia
2. Stewart A.F. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352 4 (2005) 373-379
3. Horwitz M.J., Tedesco M.B., Sereika S.M., et al. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab 88 4 (2003) 1603-1609
4. Nussbaum S.R., Gaz R.D., and Arnold A. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med 323 19 (1990) 1324-1328
5. Seymour J.F., and Gagel R.F. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 82 5 (1993) 1383-1394
6. Horwitz M., and Stewart A.F. Hypercalcemia associated with malignancy. In: Favus M.J. (Ed). Primer on the metabolic bone diseases and disorders of mineral metabolism. 6th edition (2006), American Society for Bone and Mineral Research, Washington, DC 195-199
7. Roodman G.D. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 80 Suppl 8 (1997) 1557-1563
8. Deftos L.J. Hypercalcemia in malignant and inflammatory diseases. Endocrinol Metab Clin North Am 31 1 (2002) 141-158
9. Hutchesson A.C., Bundred N.J., and Ratcliffe W.A. Survival in hypercalcaemic patients with cancer and co-existing primary hyperparathyroidism. Postgrad Med J 71 831 (1995) 28-31
10. Body J.J. Hypercalcemia of malignancy. Semin Nephrol 24 1 (2004) 48-54
11. Major P., Lortholary A., Hon J., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19 2 (2001) 558-567
12. Halfdanarson T.R., Hogan W.J., and Moynihan T.J. Oncologic emergencies: diagnosis and treatment. Mayo Clin Proc 81 6 (2006) 835-848
13. Adrogue H.J., and Madias N.E. Hyponatremia. N Engl J Med 342 21 (2000) 1581-1589
14. Ellison D.H., and Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 356 20 (2007) 2064-2072
15. Bressler R.B., and Huston D.P. Water intoxication following moderate-dose intravenous cyclophosphamide. Arch Intern Med 145 3 (1985) 548-549
16. Beck L.H. Hypouricemia in the syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 301 10 (1979) 528-530
17. Ayus J.C., and Arieff A.I. Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. JAMA 281 24 (1999) 2299-2304
18. Laureno R., and Karp B.I. Myelinolysis after correction of hyponatremia. Ann Intern Med 126 1 (1997) 57-62
19. Verbalis J.G., Goldsmith S.R., Greenberg A., et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 120 11 Suppl 1 (2007) S1-21
20. Soupart A., Ngassa M., and Decaux G. Therapeutic relowering of the serum sodium in a patient after excessive correction of hyponatremia. Clin Nephrol 51 6 (1999) 383-386
21. Bertrand M., Presant C.A., Klein L., et al. Iatrogenic superior vena cava syndrome. A new entity. Cancer 54 2 (1984) 376-378
22. Otten T.R., Stein P.D., Patel K.C., et al. Thromboembolic disease involving the superior vena cava and brachiocephalic veins. Chest 123 3 (2003) 809-812
23. Abner A. Approach to the patient who presents with superior vena cava obstruction. Chest 103 Suppl 4 (1993) 394S-397S
24. Wilson L.D., Detterbeck F.C., and Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med 356 18 (2007) 1862-1869
25. Arinc S., Gonlugur U., Devran O., et al. Prognostic factors in patients with small cell lung carcinoma. Med Oncol (2009) [Epub ahead of print]
26. Urban T., Lebeau B., Chastang C., et al. Superior vena cava syndrome in small-cell lung cancer. Arch Intern Med 153 3 (1993) 384-387
27. Nguyen N.P., Borok T.L., Welsh J., et al. Safety and effectiveness of vascular endoprosthesis for malignant superior vena cava syndrome. Thorax 64 2 (2009) 174-178
28. Lanciego C., Chacon J.L., Julian A., et al. Stenting as first option for endovascular treatment of malignant superior vena cava syndrome. AJR Am J Roentgenol 177 3 (2001) 585-593
29. Rizvi A.Z., Kalra M., Bjarnason H., et al. Benign superior vena cava syndrome: stenting is now the first line of treatment. J Vasc Surg 47 2 (2008) 372-380
30. Cheng S. Superior vena cava syndrome: a contemporary review of a historic disease. Cardiol Rev 17 1 (2009) 16-23
31. DeCamp Jr. M.M., Mentzer S.J., Swanson S.J., et al. Malignant effusive disease of the pleura and pericardium. Chest 112 Suppl 4 (1997) 291S-295S
32. Warren W.H. Malignancies involving the pericardium. Semin Thorac Cardiovasc Surg 12 2 (2000) 119-129
33. Spodick D.H. Acute cardiac tamponade. N Engl J Med 349 7 (2003) 684-690
34. Reddy P.S., Curtiss E.I., O'Toole J.D., et al. Cardiac tamponade: hemodynamic observations in man. Circulation 58 2 (1978) 265-272
35. Shabetai R. Pericardial and cardiac pressure. Circulation 77 1 (1988) 1-5
36. Swami A., and Spodick D.H. Pulsus paradoxus in cardiac tamponade: a pathophysiologic continuum. Clin Cardiol 26 5 (2003) 215-217
37. Tsang T.S., Oh J.K., and Seward J.B. Diagnosis and management of cardiac tamponade in the era of echocardiography. Clin Cardiol 22 7 (1999) 446-452
38. Tsang T.S., and Seward J.B. Management of pericardial effusion: safety over novelty. Am J Cardiol 83 4 (1999) 640
39. Merce J., Sagrista-Sauleda J., Permanyer-Miralda G., et al. Should pericardial drainage be performed routinely in patients who have a large pericardial effusion without tamponade?. Am J Med 105 2 (1998) 106-109
40. Maruyama R., Yokoyama H., Seto T., et al. Catheter drainage followed by the instillation of bleomycin to manage malignant pericardial effusion in non-small cell lung cancer: a multi-institutional phase II trial. J Thorac Oncol 2 1 (2007) 65-68
41. Moriya T., Takiguchi Y., Tabeta H., et al. Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primary non-small-cell lung cancer. Br J Cancer 83 7 (2000) 858-862
42. Kaira K., Takise A., Kobayashi G., et al. Management of malignant pericardial effusion with instillation of mitomycin C in non-small cell lung cancer. Jpn J Clin Oncol 35 2 (2005) 57-60
43. Kunitoh H., Tamura T., Shibata T., et al. A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). Br J Cancer 100 3 (2009) 464-469
44. Vaitkus P.T., Herrmann H.C., and LeWinter M.M. Treatment of malignant pericardial effusion. JAMA 272 1 (1994) 59-64
45. Allen K.B., Faber L.P., Warren W.H., et al. Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage. Ann Thorac Surg 67 2 (1999) 437-440
46. Georghiou G.P., Stamler A., Sharoni E., et al. Video-assisted thoracoscopic pericardial window for diagnosis and management of pericardial effusions. Ann Thorac Surg 80 2 (2005) 607-610
47. Pui C.H. Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother 3 4 (2002) 433-442
48. Pui C.H., Mahmoud H.H., Wiley J.M., et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 19 3 (2001) 697-704
49. Jeha S., Kantarjian H., Irwin D., et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 19 1 (2005) 34-38
50. Jeha S., and Pui C.H. Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome. Contrib Nephrol 147 (2005) 69-79
51. Cairo M.S., and Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127 1 (2004) 3-11
52. Coiffier B., Altman A., Pui C.H., et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26 16 (2008) 2767-2778
53. Coiffier B., Mounier N., Bologna S., et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 21 23 (2003) 4402-4406
54. Abrahm J.L., Banffy M.B., and Harris M.B. Spinal cord compression in patients with advanced metastatic cancer: "all I care about is walking and living my life". JAMA 299 8 (2008) 937-946
55. Gilbert R.W., Kim J.H., and Posner J.B. Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol 3 (1978) 40-51
56. Cole J.S., and Patchell R.A. Metastatic epidural spinal cord compression. Lancet Neurol 7 (2008) 459-466
57. Kwok Y., Tibbs P.A., and Patchell R.A. Clinical approach to metastatic epidural spinal cord compression. Hematol Oncol Clin North Am 20 (2006) 1297-1305
58. Ushio Y., Posner R., Posner J.B., et al. Experimental spinal cord compression by epidural neoplasms. Neurology 27 (1977) 422-429
59. Kato A., Ushio Y., Hayakawa T., et al. Circulatory disturbance of the spinal cord with the epidural neoplasm in rats. J Neurosurg 63 (1985) 260-265
60. Schiff D. Spinal cord compression. Neurol Clin 21 1 (2003) 67-86
61. Deyo R.A., Rainville J., and Kent D.L. What can the history and physical examination tell us about low back pain?. JAMA 268 6 (1992) 760-765
62. Makris A., and Kunkler I.H. The Barthel index in assessing the response to palliative radiotherapy in malignant spinal cord compression: a prospective audit. Clin Oncol 7 2 (1995) 82-86
63. Li K.C., and Poon P.Y. Sensitivity and specificity of MRI in detecting malignant spinal cord compression and in distinguishing malignant from benign compression fractures of the vertebrae. Magn Reson Imaging 6 5 (1988) 547-556
64. Heimdal K., Hirschberg H., Slettebo H., et al. High incidence of serious side effects of high dose dexamethasone treatment in patients with epidural spinal cord compression. J Neurooncol 12 2 (1992) 141-144
65. Sorensen S., Helweg-Larsen S., Mouridsen H., et al. Effect of high dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer 30A 1 (1994) 22-27
66. Vecht C.J., Haaxma-Reiche H., van Putten W.L., et al. Initial bolus of conventional versus high dose dexamethasone in metastatic spinal cord compression. Neurology 39 (1989) 1255-1257
67. Rades D., Karstens J.H., Hoskin P.J., et al. Escalation of radiation dose beyond 30 Gy in 10 fractions for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 67 2 (2007) 525-531
68. Loblaw D.A., Smith K., Lockwood G., et al. The Princess Margaret Hospital experience of malignant spinal cord compression [abstract]. Proc Am Soc Clin Oncol 22 (2003) 119
69. Patchell R.A., Tibbs P.A., Regine W.F., et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366 (2005) 643-648
70. Tosoni A., Ermani M., and Brandes A. The pathogenesis and treatment of brain metastases: a comprehensive review. Crit Rev Oncol Hematol 55 (2004) 199-215
71. Peacock K.H., and Lesser G.J. Current therapeutic approaches in patients with brain metastases. Curr Treat Options Oncol 7 (2006) 479-489
72. Lee E.L.T., and Armstrong T. Increased intracranial pressure. Clin J Oncol Nurs 12 1 (2008) 37-41
73. Barker F. Surgical and radiosurgical management of brain metastases. Surg Clin North Am 85 (2005) 329-345
74. Sirven J.I., Wingerchuk D.M., Drazkowski J.F., et al. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 79 12 (2004) 1489-1494
75. Mullen E.C., and Wang M. Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemia. Clin J Oncol Nurs 11 1 (2007) 87-95
76. Buxbaum J. Hyperviscosity syndrome in dysproteinemias. Am J Med Sci 264 (1972) 123-126
77. Menke M.N., Feke G.T., McMeel J.W., et al. Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenström's macroglobulinemia. Invest Ophthalmol Vis Sci 49 3 (2008) 1157-1160
78. Vitolo U., Ferreri A., and Montoto S. Lymphoplasmacytic lymphoma-Waldenström's macroglobulinemia. Crit Rev Oncol Hematol 67 (2008) 172-185
79. Menke M.N., Feke G.T., McMeel J.W., et al. Hyperviscosity-related retinopathy in Waldenström macroglobulinemia. Arch Ophthalmol 124 (2006) 1601-1606
80. Chiang C.C., Begley S., and Henderson S.O. Central retinal occlusion due to hyperviscosity syndrome. J Emerg Med 18 (2000) 23-26
81. Zarkovic M., and Kwaan H.C. Correction of hyperviscosity by apheresis. Semin Thromb Hemost 29 (2003) 535-542
82. Inaba H., Fan Y., Pounds S., et al. Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer 113 3 (2008) 522-529
83. Majhail N.S., and Lichtin A.E. Acute leukemia with a very high leukocyte count: confronting a medical emergency. Cleve Clin J Med 71 8 (2004) 633-637
84. Porcu P., Cripe L.D., Ng E.W., et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma 39 1-2 (2000) 1-18
85. Porcu P., Farag S., Marcucci G., et al. Leukocytoreduction for acute leukemia. Ther Apher 6 (2002) 15-23
86. Noppen M., Meysman M., D'Haese J., et al. Interventional bronchoscopy: 5-year experience at the Academic Hospital of the Vrije Universiteit Brussel (AZ-VUB). Acta Clin Belg 52 6 (1997) 371-380
87. Chhajed P.N., Baty F., Pless M., et al. Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction. Chest 130 6 (2006) 1803-1807
88. Wood D.E., Liu Y.H., Vallieres E., et al. Airway stenting for malignant and benign tracheobronchial stenosis. Ann Thorac Surg 76 1 (2003) 167-172 [discussion: 173-4]
89. Chin C.S., Litle V., Yun J., et al. Airway stents. Ann Thorac Surg 85 2 (2008) S792-S796
90. Wood D. Airway stenting. Chest Surg Clin N Am 13 2 (2003) 211-229
91. Freitag L., Tekolf E., Steveling H., et al. Management of malignant esophagotracheal fistulas with airway stenting and double stenting. Chest 110 5 (1996) 1155-1160
92. Dumon J.F., Cavaliere S., and Diaz-Jiminez J.P. Seven-year experience with the Dumon prosthesis. J Bronchol 31 (1996) 6-10
93. Lemaire A., Burfeind W.R., Toloza E., et al. Outcomes of tracheobronchial stents in patients with malignant airway disease. Ann Thorac Surg 80 2 (2005) 434-437 [discussion: 437-8]
94. Makris D., and Marquette C.H. Tracheobronchial stenting and central airway replacement. Curr Opin Pulm Med 13 4 (2007) 278-283
95. Cavaliere S., Venuta F., Foccoli P., et al. Endoscopic treatment of malignant airway obstructions in 2,008 patients. Chest 110 6 (1996) 1536-1542
96. Han C.C., Prasetyo D., and Wright G.M. Endobronchial palliation using Nd:YAG laser is associated with improved survival when combined with multimodal adjuvant treatments. J Thorac Oncol 2 1 (2007) 59-64
97. Chella A., Ambrogi M.C., Ribechini A., et al. Combined Nd-YAG laser/HDR brachytherapy versus Nd-YAG laser only in malignant central airway involvement: a prospective randomized study. Lung Cancer 27 3 (2000) 169-175
98. Suh J.H., Dass K.K., Pagliaccio L., et al. Endobronchial radiation therapy with or without neodymium yttrium aluminum garnet laser resection for managing malignant airway obstruction. Cancer 73 10 (1994) 2583-2588